News

Therapy resistance decoded
Enlarge image

ScienceFrance

Therapy resistance decoded

03.12.2012 - French researchers have identified how the body’s immune systems triggers therapy resistance to the cancer drugs gemcitabine and 5-fluorouracil.

The researchers, headed by François Ghiringhelli from INSERM in Dijon, found that in mice, the drugs activate a protein complex, termed Nlrp3 inflammasome, in myeloid derived suppressor cells. This activation leads to the release of the immune cell interleukin (IL)-1 beta, which then skews T immune cells to produce protumorigenic IL-17 and results in enhanced growth of tumours in mice (Nature Medicine, doi: 10.1038/nm.2999). 

The chemotherapeutics were more efficacious at inhibiting tumour growth in mice lacking Nlrp3 or IL-17, or treated with an IL-1 receptor antagonist. The findings suggest that targeting the inflammasome pathway in conjunction with chemotherapy may improve its tumour killing efficacy by preventing the induction of protumorigenic immune responses.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/therapy-resistance-decoded.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%

TOP

  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%
  • BIOINVENT INTERNATIONAL AB (S)2.56 SEK12.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%

TOP

  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015